Efficiency without Risk. Compliance without Compromise.

The FDA holds the Sponsor—not the software provider or AI tool—accountable for the content. A “machine-made error” is still a regulatory failure.

For decades, the Clinical Study Report (CSR) has been the bedrock of drug approval. Today, the pressure to submit faster is colliding with the emergence of Artificial Intelligence. While AI promises to slash drafting time, it introduces a new frontier of regulatory risk, from data “hallucinations” to catastrophic privacy breaches.

Is your team prepared to defend an AI-assisted report during an FDA audit?

In this webinar, we provide the strategic blueprint for integrating Large Language Models (LLMs) into your medical writing workflow without sacrificing the clinical rigor the FDA demands.  Following five points must be kept in mind before using AI tools in writing Clinical Study Reports.

1. Writing a CSR isn’t just about stringing sentences together; it’s about data integrity. 

2. AI often prioritizes fluency over factual accuracy. AI might miss the clinical significance of a specific Adverse Event (AE) that a medical writer would immediately flag as a trend.

3. Uploading raw patient data or proprietary randomization schemes into public or unsecured AI models violates HIPAA and GDPR, posing a massive legal risk to the Sponsor.

4. AI may describe a secondary endpoint differently in the Executive Summary than it does in the Results section, leading to “Refusal to File” (RTF) actions by the FDA due to internal contradictions.

5. AI can summarize what happened, but it struggles to explain why it happened in the context of the study’s specific biological mechanism.

“Rather than avoiding AI, this webinar will teach you how to leverage it as a tool within an ‘AI-Human Hybrid’ workflow. The speaker will explain how to use AI tools effectively to follow ICH E3 guidelines while drafting Sections 1–9 of a Clinical Study Report (CSR). Additionally, you will learn how to finalize the Efficacy Evaluation (Section 11), the Safety Evaluation (Section 12), and the Discussion and Overall Conclusions (Sections 13–14).” The speaker will provide the strategies for “Audit-Ready” AI Content Prompt Engineering for CSRs, The AI Audit Trail to maintain transparency during a BIMO audits.

Key Learning Objectives:

• Identify the top 5 risks of using AI in regulatory writing.

• Understand why the FDA’s focus on “Data Integrity” makes unverified AI content a submission-killer.

• Learn a workflow that cuts CSR drafting time by 40% without sacrificing clinical accuracy.

• Establish internal SOPs for the ethical and secure use of AI in clinical trial documentation.                                                                        

Who will benefit: 

1. Regulatory affairs professionals
2. Senior management executives (CEO, COO, CFO, etc)
3. Documentation management personnel
4. Records and storage personnel
5. Drug discovery and development professionals (R&D and CMC)
6. Clinical trial managers
7. Project Managers and Clinical trial specialists
8. Regulatory Compliance Associates and Managers
9. People investing in FDA-regulated product development project.